318
Participants
Start Date
November 5, 2019
Primary Completion Date
December 8, 2020
Study Completion Date
December 8, 2020
Mexidol
50 mg/ml IV solution, 250 mg tablets
Placebo
Placebo IV solution, Placebo tablets
"Centre for Neurology and Neurorehabilitation n.a. N. M. Madzhido, OOO Neyromed Servis", Tashkent
"Federal State Budget Research Institution Research Center of Neurology", Moscow
"Federal State Budget Educational Institution of Further Professional Education Russian Medical Academy of Continuous Professional Education", Moscow
"OOO Centre for Evidence-Based Medicine", Yaroslavl
"State Budget Healthcare Institution of the Yaroslavl Region Clinical Hospital No.2", Yaroslavl
"Regional Budget Healthcare Institution Ivanovo Regional Clinical Hospital", Ivanovo
"Federal State Budget Military Educational Institution of Higher Education Military Medical Academy n.a. S.M.Kirov", Saint Petersburg
City Hospital No.40 of the Kurortny District, Sestroretsk
"Private Healthcare Institution Clinical Hospital RR-Medicine of Voronezh", Voronezh
"Federal State Budget Educational Institution of Higher Education Kazan State Medical University", Kazan'
"Municipal Autonomous Healthcare Insitution of the Order of the Red Banner of Labour City Clinical Hospital No.1", Chelyabinsk
"State Budget Healthcare Institution of the Sverdlovsk Region Sverdlovsk Regional Clinical Hospital No.1", Yekaterinburg
"State Budget Healthcare Institution of the Novosibirsk Region City Hospital № 34", Novosibirsk
"Federal State Budget Research Institution Federal Research Center for Fundamental and Translational Medicine", Novosibirsk
Lead Sponsor
Pharmasoft
INDUSTRY